Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are bacterial infections in which a large abnormal region of tissue is formed near wounds
Acute bacterial skin and skin structure infections (ABSSSI)
are common, especially among
children. The reason for this is that children's bladders do not fully develop
until the age of two, making it easier for bacteria to travel up into the lungs
and the mouth. In addition, certain drugs such as some antibiotics can cause
acute bacterial infections as well.
One of the most common drugs used for treating such infections is
Fluconazole (FLZ), which is administered orally on a daily basis in most cases.
For children who suffer from acute
bacterial skin and skin structure infections (ABSSSI), the U.S. Food
and Drug Administration (FDA) has approved the use of fluconazole (FLZ) in
combination with other drugs to effectively treat the infection.
Children who suffer from this condition should be administered at least
one course of a combination treatment containing either amikacin or econazole,
at least seven days apart. If the infection does not respond adequately in this
amount of time, additional courses may be needed. Some of these side effects
include vomiting, nausea, and abdominal pain.
Children with complicated skin structure infections
often have difficulty maintaining appropriate fluid and electrolyte balance.
This can lead to complications, such as vomiting, dehydration, electrolyte
imbalances, fever, and shock. Considering these complications, antibiotics are
not usually administered for this condition. On the other hand, a large
percentage of patients with acute bacterial skin structure infections respond
to antibiotics. For instance, in March 2021, the U.S. Food and Drug
Administration (FDA) granted approval for KIMYRSA (Melinta Therapeutics) for
treatment of acute bacterial skin and
skin structure infections (ABSSSI) in adult patients.
As an alternative to antibiotics, acid reducers are often used in the
treatment of acute bacterial skin and skin structure
infections (ABSSSI). Acid reducers inhibit the synthesis of all known
types of bacteria, including Escherichia coli, Staphylococcus aureus, and
yeast. Limited clinical studies demonstrate that acid reducers improve both the
quality and duration of antibiotic therapy for bacterial skin infections caused
by Pseudomonas species. For most types of acute
bacterial skin and skin structure infections (ABSSSI), patients will be
given a single dose of the acid reducer, which can be administered up to four
times daily.
Comments
Post a Comment